StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)

Close on Nov 18, 2026Market cap $5.00MP/E –Yield –

BioLineRx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -$8.10M. The highest annual figure on record is -$8.10M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.10M–
FY2024Dec 31, 2024-$43.93M–
FY2023Dec 31, 2023-$22.72M–
FY2022Dec 31, 2022-$26.37M–
FY2021Dec 31, 2021-$23.67M–
FY2020Dec 31, 2020-$23.21M–
FY2019Dec 31, 2019-$22.73M–
FY2018Dec 31, 2018-$24.37M–
FY2017Dec 31, 2017-$20.89M–
FY2016Dec 31, 2016-$14.57M–
FY2015Dec 31, 2015-$16.85M–

More BioLineRx figures

See a number that looks wrong?